<DOC>
	<DOCNO>NCT01440829</DOCNO>
	<brief_summary>The aim study evaluate effectiveness L-ornithine-L-aspartate ( LOLA ) plasma ammonia cirrhotic patient Transjugular Intrahepatic Portosystemic Shunt ( TIPS ) procedure .</brief_summary>
	<brief_title>The Effectiveness L-ornithine-L-aspartate ( LOLA ) Plasma Ammonia Cirrhotic Patients After TIPS</brief_title>
	<detailed_description>Patients successful TIPS deployment randomize LOLA arm blank control arm . Plasma ammonia concentration measure TIPS , day 1 , day 4 day 7 TIPS .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>Cirrhotic patient refractory ascites least one episode variceal bleed No active bleeding within 5 day TIPS ChildPugh score â‰¤ 11 Signed write informed consent An age &lt; 18 year &gt; 65 year With TIPS contraindication Using drug hepatic encephalopathy neomycin , rifaximin , lactulose , lactitol branchedchain amino acid . Intake psychostimulants , sedative , antidepressant , benzodiazepine benzodiazepineantagonists Past present history hepatic encephalopathy Pregnancy breastfeed Hepatic carcinoma and/or malignancy diseases Sepsis Spontaneous bacterial peritonitis Uncontrollable hypertension Serious cardiac pulmonary dysfunction Renal failure Portal vein thrombosis History organ transplantation History HIV ( human immunodeficiency virus ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Transjugular Intrahepatic Portosystemic Shunt</keyword>
	<keyword>TIPS</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>LOLA</keyword>
	<keyword>L-ornithine-L-aspartate</keyword>
	<keyword>Refractory Ascites</keyword>
</DOC>